Lu XF, Zhang HW, Chang X, Guo YZ. F-box protein 22: A prognostic biomarker for colon cancer associated with immune infiltration and chemotherapy resistance. World J Gastrointest Oncol 2025; 17(4): 102913 [DOI: 10.4251/wjgo.v17.i4.102913]
Corresponding Author of This Article
Yong-Ze Guo, MD, Professor, Department of Gastroenterology, Affiliated Hospital of Hebei Engineering University, No. 81 Congtai Road, Congtai District, Handan 056002, Hebei Province, China. guoyongze69@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Xiao-Fei Lu, Department of Clinical Medicine, Hebei University of Engineering, Handan 056002, Hebei Province, China
Hong-Wei Zhang, Xiao Chang, Yong-Ze Guo, Department of Gastroenterology, Affiliated Hospital of Hebei Engineering University, Handan 056002, Hebei Province, China
Co-first authors: Xiao-Fei Lu and Hong-Wei Zhang.
Author contributions: Lu XF and Zhang HW contributed equally to this manuscript as co-first authors. Lu XF, Zhang HW, Chang X, and Guo YZ designed and coordinated the study, drafted the manuscript, and interpreted the data; Lu XF, Zhang HW, and Chang X performed the experiments, acquired and analyzed data; and all authors providing their approval for the final version of the article.
Institutional review board statement: The study was reviewed and approved by institutional ethics board of Affiliated Hospital of Hebei Engineering University (No.: 2024[K]005-01).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Data are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Ze Guo, MD, Professor, Department of Gastroenterology, Affiliated Hospital of Hebei Engineering University, No. 81 Congtai Road, Congtai District, Handan 056002, Hebei Province, China. guoyongze69@126.com
Received: November 28, 2024 Revised: January 10, 2025 Accepted: February 21, 2025 Published online: April 15, 2025 Processing time: 117 Days and 9.4 Hours
Core Tip
Core Tip: The precise role of the F-box protein 22 (FBXO22) gene in post-operative colon cancer patients remains to be fully elucidated. Utilizing bioinformatics assessments alongside cellular experimentation, researchers observed that the expression of the FBXO22 gene is markedly higher in colon cancer tissues when compared to normal colonic tissues. Patients suffering from colon cancer who present with increased FBXO22 gene levels tend to have decreased survival rates and show resistance to various chemotherapy agents. The elevated levels of the FBXO22 gene are associated with a reduction in the infiltration of immune cells that target tumors. Laboratory experiments demonstrate that reducing the activity of the FBXO22 gene hinders the growth and movement of colon cancer cells. The evidence suggests that the FBXO22 gene may facilitate the advancement of colon cancer, be associated with the onset of resistance to chemotherapy among post-operative colon cancer patients, and could act as an indicator of poor outcomes for these individuals. Consequently, targeting FBXO22 could represent a novel approach for treating colon cancer.
